Home › Non-Small Cell Lung Cancer › Connecticut
Non-Small Cell Lung Cancer clinical trials in Connecticut
54 studies for Non-Small Cell Lung Cancer are looking for participants at sites in Connecticut.
Cities in Connecticut
- New Haven40 studies
- East Norwalk19 studies
- Bridgeport15 studies
- Hartford11 studies
- Stamford9 studies
- Waterbury6 studies
- Norwich5 studies
- New London5 studies
- Norwalk3 studies
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
- Yale University, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 13, 2026 · NCT07111520A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- University of Connecticut Health Center ( Site 0130), Farmington
- Stamford Hospital ( Site 0126), Stamford
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07190248Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Hartford HealthCare - Avon, Avon
- Hartford Hospital, Hartford
- Hartford HealthCare - Manchester, Manchester
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06498635Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Smilow Cancer Hospital-Derby Care Center, Derby
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich
- and 9 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04267848A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Stamford Hospital ( Site 0136), Stamford
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06345729Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
- Eastern Connecticut Hematology and Oncology Associates, Norwich
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06472245A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Stamford Hospital ( Site 0083), Stamford
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT06312137Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Yale-New Haven Hospital-Yale Cancer Center, New Haven
- Smilow Cancer Hospital Phase 1 Unit, New Haven
- and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT04557449A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
- Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 10, 2026 · NCT07503808A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Yale University School of Medicine ( Site 0201), New Haven
- Eastern CT Hematology & Oncology Associates ( Site 0202), Norwich
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06623422A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Smilow Cancer Center at Yale-New Haven ( Site 3253), New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT07513376A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Smilow Cancer Hospital - Yale New Haven Health, New Haven
- Yale - New Haven Hospital - Yale Cancer Center, New Haven
- Smilow Cancer Hospital Phase 1 Unit, New Haven
- and 1 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT07090499A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Hartford Hospital, Hartford
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT06793215A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- Yale Cancer Center, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 5, 2026 · NCT05789082Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Hartford Hospital (HH), Hartford
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06890598A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
- Yale University - Cancer Center, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06706076VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- Hartford Hospital (site 210), Hartford
RecruitingPhase 1/2
Ages 18 to 80 · All sexes · Updated Nov 4, 2026 · NCT03556228SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
- Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07857616A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Yale University School of Medicine, New Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06119581Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
- Eastern Connecticut Hematology and Oncology Associates, Norwich
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT07397338A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07578571A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
- Yale University, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06667908M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors
- Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT07166601Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Eastern Connecticut Hematology and Oncology Associates, Norwich
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 30, 2026 · NCT04613596Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
- Yale New Haven Hospital, Yale Cancer Center, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT05098132A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, West Haven
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06692738Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma
- Yale University, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06014827A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Yale Cancer Center, New Haven
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06172478Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, New Haven
RecruitingPhase 2
Ages 18 to 95 · All sexes · Updated Oct 21, 2026 · NCT05061550Study of PF-07248144 in Advanced or Metastatic Solid Tumors
- Smilow Cancer Hospital at Yale - New Haven, New Haven
- Yale-New Haven Hospital- Yale Cancer Center, New Haven
- Smilow Cancer Hospital Phase 1 Unit, New Haven
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT04606446Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- Yale University School of Medicine - Yale Cancer Center, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT05786924Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Smilow Cancer Hospital-Derby Care Center, Derby
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield
- Smilow Cancer Hospital Care Center - Guilford, Guilford
- and 4 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT06116682Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Smilow Cancer Hospital-Derby Care Center, Derby
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield
- Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury
- and 10 more
RecruitingPhase 2
18 Minutes · All sexes · Updated Oct 9, 2026 · NCT06031688A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Hartford Healthcare, Hartford
- Yale University, New Haven
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT07070232Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Smilow Cancer Hospital-Derby Care Center, Derby
- Smilow Cancer Hospital Care Center-Fairfield, Fairfield
- Smilow Cancer Hospital Care Center at Greenwich, Greenwich
- and 9 more
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 9, 2026 · NCT06616584The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Yale Cancer Center, New Haven
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Oct 2, 2026 · NCT04585750Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #62, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
- Kivu Trial Site, New Have
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07229313Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Yale University, Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Yale Cancer Center, New Haven
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT07349537From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.